Business Wire

IL-SHIPPEO

2.4.2024 11:00:27 CEST | Business Wire | Press release

Share
Shippeo Named a Leader in the 2024 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms, Announces Record Growth in North America and APAC

Shippeo has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms. The global multimodal shipment visibility platform was also recently named a Customers’ Choice by Gartner® in the October 2023 Gartner Peer Insights™ “Voice of the Customer”: Real-Time Transportation Visibility Platforms report, scoring the highest customer recommendation willingness rate of all providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402784237/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Shippeo)

“We are delighted to be recognized as a Leader in this latest Gartner research,” says Shippeo CEO & co-founder, Pierre Khoury. “We are also deeply thankful for the support of our wonderful customers and ecosystem partners, and incredibly proud of our talented teams. As the real-time transportation visibility (RTTV) market continues to mature in North America, Europe, and increasingly across APAC, companies are realizing the significant value visibility brings. From increasing customer NPS with more premium delivery experiences, to reducing operating costs, optimizing processes and cash flow, and monitoring and reducing carbon emissions, our platform is being recognized as an important enabler of next-generation supply chains.”

Strong growth and market momentum in North America, Asia Pacific and Europe

Over the past two years, the company’s customer base tripled. In 2023, the North American revenue grew 153% year over year, with 25% of all new revenue generated having come from companies in this region switching to Shippeo from another provider. Notable new North American customers include Amazon, Barilla, and Palermo Villa, Inc. (dba Palermo’s Pizza). The company also significantly grew its customer base in Asia Pacific, welcoming some of the region’s most recognizable brands, including Yamaha Motor. Notable customers joining in other parts of the world include Arlanxeo, Birra Peroni, DP World, Evonik, Fujifilm and Hartmann Group.

“Our approach to visibility with a greater focus on data quality and customer support has resonated extremely well with the RTTV market in North America,” says Lucien Besse, COO & co-founder at Shippeo. “Since 2020, our partnership with e2open has blossomed into a powerhouse collaboration. Through close cooperation and a shared commitment to excellence, we've achieved remarkable success together, in North America and abroad. This enduring partnership underscores our collective ability to innovate and thrive in today's dynamic landscape.”

Global multimodal visibility network

With established regional head offices in Chicago for the Americas, Singapore for APAC, and Paris for Europe, Shippeo’s network now tracks more than 50 million shipments a year across all modes, in more than 130 countries on six continents, with a 258,000-strong carrier network. Their ocean visibility network covers 99% of the world’s containerships thanks to integrations with major shipping lines. The company’s partner network has also enjoyed continued momentum, now comprising over 1000 system integrations with TMS, WMS, ERPs and telematics devices, representing a 30% increase since the start of 2022. Key strategic partners include e2open, SAP, Infor, Tesisquare, Alpega, Oracle, Siemens, Google, Snowflake, Microsoft, and BlueYonder.

The most recommended provider for three years running

Shippeo has had the highest recommendation rate of all providers on Gartner Peer Insights for over three years. In October 2023, the company was positioned in the Customers’ Choice Quadrant, having scored a 96% recommendation rate, the highest of all providers (based on 116 reviews as of August 2023).

www.shippeo.com/press-releases/shippeo-named-a-leader-in-the-2024-gartner-magic-quadrant-for-real-time-transportation-visibility-platforms

Disclaimer:
GARTNER is a registered trademark and service mark and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
G
artner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2024” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 26 March 2024.

Gartner, “Voice of the Customer for Real-Time Transportation Visibility Platforms”, by Peer Contributors, 31 October 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular Purpose.

Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402784237/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye